Kelyniam Global announced that it has acquired MED-ALLY, as part of its product diversification initiative.

MED-ALLY applies custom, proprietary neuromodulation technology to create a number of external and implantable medical devices that can be used to treat a wide array of conditions including chronic pain management, urinary incontinence, sleep apnea, Tinnitus and Deep Brain Stimulation applications such as Alzheimer’s, Epilepsy, and Parkinson’s disease.

Kelyniam’s current product line is made up of precise and novel, customized PEEK cranial and facial implants used to fill bony voids caused by trauma, birth defects or disease. Its streamlined CAD/CAM design and manufacturing techniques enable Kelyniam to deliver patient-specific PEEK implants to surgeons in as little as 24 hours from the receipt of an order – a timeframe which is unmatched in its industry.

The ability to provide custom PEEK implants quickly and accurately can reduce the time between trauma and implantation and provides surgeons additional treatment options.

"Kelyniam’s mission is to develop and manufacture medical devices that significantly improve medical care, surgical outcomes and patient quality of life, and our acquisition of MED-ALLY greatly enhances our ability to do just that," said Tennyson Anthony, president and CEO of Kelyniam Global.

MED-ALLY founders, John Mulvihill and Raja Hitti, bring more than 50 years of combined medical device design, development, manufacturing, sales and marketing experience that will have a positive impact on Kelyniam customers globally.

MED-ALLY has agreements with multiple early-stage neuromodulation companies to deliver an active implantable medical device system to treat new therapeutic indications not currently available in the market. A recent market study from Neurotech Reports estimates the neuromodulation medical device market to be $4 billion and growing more than 18% annually.